Modern obesity trials are inherently complex, but the momentum behind these therapeutics has never been greater. With over ...

Rhonda Pacheco, who oversaw Zepbound’s launch, will run Takeda’s U.S. business. Elsewhere, early data suggested Maze might have a “best-in-class” rare disease drug and Arrowhead challenged Ionis in ...

One analysts called the Phase 2 study results a “best-case scenario” for a drug Rapport is developing to treat focal onset ...

Updated findings from Wave’s pioneering trial continued to show its RNA editing therapy is working as intended, but wasn’t as ...

Still, physicians so far are being careful with GLP-1s in oncology, particularly with pancreatic cancer patients or those ...

An HHS spokesperson confirmed Prasad's reappointment as chief medical and scientific officer, one month after his surprising ...

A licensing deal worth at least $200 million will give Novartis access to a preclinical RNA medicine designed to combat ...

The agency says it’s open to offering speedy approval pathways for new pain medications that can fight the ongoing opioid ...

Capsida is investigating the root cause of the death, which occurred in the first patient treated in a trial of the company’s ...

LB Pharmaceuticals, which has a schizophrenia medicine headed for late-stage testing, broke one of the longest droughts for ...

The drugmaker’s new CEO said the moves will help the company be more agile as it deals with competition in the obesity market ...

The venture arms of Merck KGaA and Novartis are among the investors involved in raising $67 million for NRG Therapeutics, ...